Friday Was an Anomaly<br />By Rev Shark<br />RealMoney.com Contributor<br />6/29/2009 9:01 AM EDT <br /><br />Nothing is so difficult as not deceiving oneself. <br />-- Ludwig Wittgenstein<br /><br />Changes to the Russell indices on Friday produced some of the wildest and most deceptive action we have seen in some times. Although the major indices didn't move all that much, volume was huge and dozens of stocks moved 20% or more as index funds scrambled to gain the exposure they needed. Some of the stocks being added to the Russell 2000 and Microcap indices are particularly thinly traded, and the action was downright absurd in many cases. Much of it will probably reverse quickly, so there should be some crazy action again over the next couple of days. <br /><br />What makes this particularly difficult is that if you weren't aware of what was going on with the indexing, there were some really fantastic charts. There were big-volume breakouts that you'd normally expect to see gain momentum. When stocks move like that, there's usually some solid fundamental reason behind the move, and there may be good reasons you'd want to jump in and maybe chase it higher. <br /><br />That was not the case on Friday. These stocks moved simply due to indexing; there is no reason at all to suspect that the momentum will continue now that the funds have the shares they need. The ironic thing about these index funds is that it really doesn't matter to them what they paid for a stock. They simply need to have their shares so that their funds reflect what is happening in the index. <br /><br />To make things even trickier, we also had end-of-the-quarter window-dressing games to go with the indexing. Some of the big-cap momentum favorites like Apple (AAPL) , Baidu (BIDU) , Amazon (AMZN) and Shanda (SNDA) saw some very energetic action as money managers try to add performance points before the quarter ends. <br /><br />Overall, while the action was favorable in the indices and extremely good in some individual stocks, it leaves us with a rather muddled market. We have been able to rally back to some key resistance levels on good volume, but we haven't quite broken through. The big problem is that there is no good reason to believe the momentum on Friday will be sustained. We really have to be skeptical of what the charts are saying at this point because the action was so artificial. <br /><br />We have a positive start this morning as some of the strength from Friday carries over. There will be some pressure to at least preserve the mark-ups through tomorrow, but quite often end-of-the-quarter games come to an end a day or two early. <br /><br />We will have to be patient as the market deals with Friday's action. It was something very exceptional that you don't see too often, and we can't treat it like it like a normal market. We'll have a better sense of the health of the market soon -- just be careful about reading anything into what we saw on Friday. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />Select oil/gas names showing strength: SNP +3.3%, STO +2.0%, RDS.A +1.6%, TOT +1.1%, PBR +1.1%... Select financial names ticking higher: SLM +4.1% (tgt raised to $16 at FBR Capital due to improving student loan spreads and increased earnings potential), DFS +4.0% (upgraded to Outperform from Market Perform at Keefe Bruyette), LYG +3.5% (upgraded to Buy at Goldman- FT.com), HIG +2.8%, RBS +2.0%, AZ +2.0%, FITB +1.7%, AXA +1.6%, STI +1.3%, WFC +1.2%, BCS +1.1% (upgraded to Hold from Sell at Societe Generale)... Other news: DCGN +55.6% (says discovers a gene linked to risk of kidney stones and osteoporosis), CYTR +22.2% (reports "favorable" progress update for its pivotal Phase 2 clinical trial with Tamibarotene as a third-line treatment for acute promyelocytic leukemia), EVTC +13.1% (announced the successful completion of the first Phase I study with its P2X7 receptor antagonist EVT 401), IOC +9.1% (Energy giants to bid for $500 mln gas project - SCMP.com), WEN +7.4% (Wendy's/Arby's mentioned positively in Barron's), SVA +6.1% (receives revised approvals for Panflu), MDRX +6.1% (still checking), CLR +5.2% (Cramer makes positive comments on MadMoney), CSIQ +3.1% (announces 120 MW in recent sales orders), SNY +2.4% (no definitive conclusions can be drawn regarding a possible causal relationship between Lantus use and the occurrence of malignancies), ELN +1.9% (Novartis in talks to buy much of Elan: Report - Reuters), NOK +1.3% (still checking), PCAR +1.1% (renews bank credit facility)... Analyst comments: TRW +11.0% ( upgraded to Overweight from Neutral at JP Morgan), JCP +4.4% (upgraded to Overweight from Equal Weight at Morgan Stanley), RGC +1.6% (upgraded to Buy at Merriman), ZBRA +1.5% (upgraded to Outperform from Neutral at RW Baird). <br /><br />Allapoole avanevad:<br /><br />M&A news: EPD -2.1% (light volume; Enterprise Prdcts and TEPPCO agree to merge forming largest publicly traded energy partnership)... Select European drug names showing weakness: GSK -1.4%, NVS -1.4%... Other news: UEC -16.9% (completed a private placement financing involving the sale of an aggregate of 9,099,834 units together with 200,000 common shares at a subscription price of $2.40 per Unit), BIIB -3.6% (reports 10th PML case in Tysabri MS patient - DJ; also downgraded to Hold at Deutsche), STT -2.8% (discloses "Wells" notice relating to ongoing investigation), WW -2.4% (Watson Wyatt and Towers Perrin to combine in a merger of equals to form Towers Watson; also downgraded to Hold from Buy at Citigroup), EPD -2.1% (Enterprise Prdcts and TEPPCO agree to merge forming largest publicly traded energy partnership)... Analyst comments: IPCM -2.7% (downgraded to Hold from Buy at Deutsche Bank).